Breaking News

DePuy Synthes Acquires Tissue Regeneration System's 3D Printing Technologies

By PR Newswire | April 20, 2017

Patient-specific implants will address unmet clinical need to treat bone defects and advance leadership in trauma.

DePuy Synthes Products Inc., part of the Johnson & Johnson Family of Companies, has acquired 3D printing technology from Tissue Regeneration Systems Inc. (TRS). The 3D printing methods developed by TRS will help enable DePuy Synthes to create patient-specific, bioresorbable implants with a unique mineral coating intended to support bone healing in patients with orthopedic and craniomaxillofacial deformities and injuries. Financial terms of the transaction have not been disclosed.
 
The acquisition from TRS brings exciting new technology with the potential to truly personalize health care solutions in Trauma, a priority platform for the business, and builds on DePuy Synthes' leadership in delivering ground-breaking innovation that improves patients' lives. With more than 50 strategic collaborations, the Johnson & Johnson Family of Companies is harnessing 3D printing technology to develop patient-specific healthcare solutions that can mean increased satisfaction and better clinical outcomes.
 
"We are systematically investing in building a pipeline of 3D printed products," said Ciro Römer, Company Group Chairman, DePuy Synthes. "The TRS technology, which will be added to the DePuy Synthes Trauma Platform, is the latest example of how we are working toward developing next-generation technologies that transform healthcare delivery with individualized solutions for patients."
 
DePuy Synthes began collaborating with TRS in 2014 through Johnson & Johnson Innovation, which seeks and invests in the best science and builds novel partnerships at all stages of development across the medical device, consumer healthcare and pharmaceutical sectors. Johnson & Johnson Innovation facilitated the collaboration between DePuy Synthes and TRS. 
 
"The acquisition of the TRS technology by DePuy Synthes is testament to our ability to identify and work collaboratively with promising early-stage companies and entrepreneurs to accelerate bringing innovative new products to market," said Robert G. Urban, Ph.D., Global Head, Johnson & Johnson Innovation. "We are excited at the potential this technology holds to help improve patient outcomes."
 
Founded in 2008, TRS is an early-stage medical device company headquartered in Plymouth, Mich., commercializing skeletal reconstruction and bone regeneration technology based on research performed at the University of Michigan and the University of Wisconsin.

Related News:

Related Markets:

Related Manufacturing:

  • Loading Orthopedic Devices with Biologics and Pharmaceuticals

    Loading Orthopedic Devices with Biologics and Pharmaceuticals

    Dr. Kevin Nelson, Founder and CSO, TissueGen Inc.||May 19, 2017
    Fiber technology enables the delivery of the therapeutic components via a biodegradable platform that can be implanted.

  • Looking Beneath the Surface

    Looking Beneath the Surface

    Sam Brusco, Associate Editor||May 19, 2017
    Surface treatments seek to improve orthopedic device usability, longevity, and bone integration.

  • Going to Extremes

    Going to Extremes

    Michael Barbella, Managing Editor||May 19, 2017
    The innovation and market value found in extremity solutions is prompting a change of heart among major orthopedic firms.